Tags

Type your tag names separated by a space and hit enter

New drug policy in childhood obesity.
Int J Obes (Lond). 2005 Sep; 29 Suppl 2:S62-5.IJ

Abstract

OBJECTIVE

To update physicians, especially paediatricians, in the rapidly developing field of pharmacotherapy of childhood and adolescent obesity.

METHODS

The paper reviews current and investigational antiobesity drugs.

RESULTS

At present, there are only few drugs approved by the Food and Drug Administration (FDA) for the treatment of adult obesity. The most important ones are sibutramine and orlistat. The FDA in the USA approved the latter drug in 2003, and it has recently been approved by the European Union for the treatment of adolescents. There are several investigational antiobesity agents but only few new and promising substances like Rimonabant (a cannabinoid receptor antagonist) and axokine (ciliary neutrotrophic factor) are already at an advanced stage of development.

CONCLUSION

In adults, it seems to be justified using drugs for long-term treatment of 'medically important' obesity. Strict guidelines concerning the treatment of obese adolescents with orlistat are needed. It is only hoped that double-blind placebo-controlled studies investigating the new and promising drugs will also include adolescents and provide sufficient scientific data to get them licensed for the treatment of obese adolescents.

Authors+Show Affiliations

Department of Paediatrics, University of Pécs, Hungary. denes.molnar@aok.pte.hu

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16385755

Citation

Molnár, D. "New Drug Policy in Childhood Obesity." International Journal of Obesity (2005), vol. 29 Suppl 2, 2005, pp. S62-5.
Molnár D. New drug policy in childhood obesity. Int J Obes (Lond). 2005;29 Suppl 2:S62-5.
Molnár, D. (2005). New drug policy in childhood obesity. International Journal of Obesity (2005), 29 Suppl 2, S62-5.
Molnár D. New Drug Policy in Childhood Obesity. Int J Obes (Lond). 2005;29 Suppl 2:S62-5. PubMed PMID: 16385755.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New drug policy in childhood obesity. A1 - Molnár,D, PY - 2005/12/31/pubmed PY - 2006/8/1/medline PY - 2005/12/31/entrez SP - S62 EP - 5 JF - International journal of obesity (2005) JO - Int J Obes (Lond) VL - 29 Suppl 2 N2 - OBJECTIVE: To update physicians, especially paediatricians, in the rapidly developing field of pharmacotherapy of childhood and adolescent obesity. METHODS: The paper reviews current and investigational antiobesity drugs. RESULTS: At present, there are only few drugs approved by the Food and Drug Administration (FDA) for the treatment of adult obesity. The most important ones are sibutramine and orlistat. The FDA in the USA approved the latter drug in 2003, and it has recently been approved by the European Union for the treatment of adolescents. There are several investigational antiobesity agents but only few new and promising substances like Rimonabant (a cannabinoid receptor antagonist) and axokine (ciliary neutrotrophic factor) are already at an advanced stage of development. CONCLUSION: In adults, it seems to be justified using drugs for long-term treatment of 'medically important' obesity. Strict guidelines concerning the treatment of obese adolescents with orlistat are needed. It is only hoped that double-blind placebo-controlled studies investigating the new and promising drugs will also include adolescents and provide sufficient scientific data to get them licensed for the treatment of obese adolescents. SN - 0307-0565 UR - https://www.unboundmedicine.com/medline/citation/16385755/New_drug_policy_in_childhood_obesity_ L2 - https://doi.org/10.1038/sj.ijo.0803084 DB - PRIME DP - Unbound Medicine ER -